UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of June 2023

 

Commission File Number: 001-12033

 

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

 

Bay & Deveaux Streets, Nassau, The Bahamas 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

 

On June 19, 2023, Nymox Pharmaceutical Corporation (the “Company”) terminated the employment of each of Mr. Christopher R. Riley, Chief Financial Officer, and Mr. Randall J. Lanham, Chief Operating Officer.

 

The Company has initiated a search for a Chief Financial Officer, and is in the process of hiring a general counsel to assume the role of Mr. Lanham.

 

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 27, 2023

 

 

NYMOX PHARMACEUTICAL CORPORATION
       
By:

/s/ Paul Averback

 

Name:

Paul Averback

  
 

Title:

President and Chief Executive Officer

  

 

 

3

 

Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Nymox Pharmaceutical Charts.
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Nymox Pharmaceutical Charts.